Haemonetics Corporation
$5.68B- Market cap
- $4.68B
- Debt
- +$1.24B
- Cash
- −$245.44M
Capital structure 79% equity / 21% debt · EV / Revenue 4.26x · EV / EBITDA 21.58x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HAE stock price at premium vs ACAD $102.92 current versus $24.99 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ACAD's multiple
Implied fair value · at HAE's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Expensive
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HAE FY 2026 (ended Mar 28, 2026) · ACAD FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 79% equity / 21% debt · EV / Revenue 4.26x · EV / EBITDA 21.58x
Capital structure 94% equity / 6% debt · EV / Revenue 4.63x · EV / EBITDA 32.92x
HAE carries the larger enterprise value at $5.68B against $4.96B; HAE trades on the lower EV / Revenue multiple (4.26x vs 4.63x); HAE on the lower EV / EBITDA (21.58x vs 32.92x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Haemonetics Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ACADIA PHARMACEUTICALS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.56x
0.25x
Net debt / EBITDA
Leverage against operating earnings
3.80x
0.85x
Cash and equivalents
Liquid reserves on the balance sheet
$245.44M
$177.70M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BECTON DICKINSON & CO
HAE vs BDX
BAXTER INTERNATIONAL INC
HAE vs BAX
LivaNova PLC
HAE vs LIVN
STERIS plc
HAE vs STE
SUPERNUS PHARMACEUTICALS, INC.
HAE vs SUPN
Sage Therapeutics, Inc.
HAE vs SAGE
Jazz Pharmaceuticals plc
HAE vs JAZZ
Alkermes plc.
HAE vs ALKS
Harmony Biosciences Holdings, Inc.
HAE vs HRMY
Krystal Biotech, Inc.
HAE vs KRYS
$1.24B
$306.51M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.